{
    "clinical_study": {
        "@rank": "6707", 
        "arm_group": {
            "arm_group_label": "dovitinib", 
            "arm_group_type": "Experimental", 
            "description": "single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications are at the discretion of the investigator based on guidance provided in the protocol and IB."
        }, 
        "brief_summary": {
            "textblock": "The study allows continued safety follow-up of single agent dovitinib in patients who are on\n      single agent dovitinib treatment in a Novartis-sponsored study which has met its primary\n      endpoint and are benefiting from the treatment as judged by the investigator."
        }, 
        "brief_title": "An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patient is currently enrolled in Novartis sponsored study, which has met its endpoint\n             and is receiving single agent oral dovitinib\n\n          -  patient is currently benefiting from treatment with single agent oral dovitinib as\n             determined by the guidelines of the parent protocol and according to the\n             investigator's clinical judgment.\n\n          -  patient has demonstated compliance\n\n          -  patient has given written informed consent.\n\n        Exclusion Criteria:\n\n          -  patient has been permanently discontinued from single agent oral dovitinib study\n             treatment in the parent study\n\n          -  patient is pregnant or nursing at the time of entry\n\n          -  women of child-bearing potential and male patients with sexual partners of\n             child-bearing potential unwilling to use highly effective methods of contraception\n             during dosing and for a specified duration after stopping study treatment\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02116803", 
            "org_study_id": "CTKI258A2X01B"
        }, 
        "intervention": {
            "arm_group_label": "dovitinib", 
            "description": "single agent dovitinib starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications are at the discretion of the investigator based on guidance provided in the protocol and IB.", 
            "intervention_name": "dovitinib", 
            "intervention_type": "Drug", 
            "other_name": "TKI258"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "solid tumors,", 
            "TKI258"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "ichaudha@montefiore.org", 
                    "last_name": "Imran Chaudhary", 
                    "phone": "718-405-8515"
                }, 
                "facility": {
                    "address": {
                        "city": "Bronx", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10467-2490"
                    }, 
                    "name": "Montefiore Medical Center SC - TKI258A2X01B"
                }, 
                "investigator": {
                    "last_name": "Sanjay A. Goel", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark", 
                        "zip": "DK-2100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pavia", 
                        "country": "Italy", 
                        "state": "PV", 
                        "zip": "27100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Torino", 
                        "country": "Italy", 
                        "state": "TO", 
                        "zip": "10153"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-city", 
                        "country": "Japan", 
                        "state": "Osaka", 
                        "zip": "545-8586"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Palma De Mallorca", 
                        "country": "Spain", 
                        "state": "Islas Baleares", 
                        "zip": "07120"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gen\u00e8ve", 
                        "country": "Switzerland", 
                        "zip": "1211"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Denmark", 
                "Italy", 
                "Japan", 
                "Spain", 
                "Switzerland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Switzerland: Swissmedic", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Netherlands: Medicines Evaluation Board (MEB)", 
                "Italy: The Italian Medicines Agency", 
                "Denmark: Danish Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence and severity of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03, unless otherwise specified; clinical laboratory tests, physical examinations, vital signs, ECGs, and cardiac imaging.", 
            "measure": "Incidence and severity of adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Until the last patient discontinues dovitinib; anticipated 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02116803"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}